Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Interleukin‐17+CD8+ T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression
Bina Menon, Nicola Gullick, Gina Walter, et al.
Arthritis & Rheumatology (2014) Vol. 66, Iss. 5, pp. 1272-1281
Open Access | Times Cited: 259

Showing 1-25 of 259 citing articles:

Psoriatic Arthritis
Christopher T. Ritchlin, Robert A. Colbert, Dafna D. Gladman
New England Journal of Medicine (2017) Vol. 376, Iss. 10, pp. 957-970
Closed Access | Times Cited: 1095
Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines
Irene Maeve Rea, David S. Gibson, Victoria McGilligan, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 1049
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B. McInnes, Philip J. Mease, Bruce Kirkham, et al.
The Lancet (2015) Vol. 386, Iss. 9999, pp. 1137-1146
Open Access | Times Cited: 788
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J. Mease, Iain B. McInnes, Bruce Kirkham, et al.
New England Journal of Medicine (2015) Vol. 373, Iss. 14, pp. 1329-1339
Open Access | Times Cited: 684
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J. Mease, Désirée van der Heijde, Christopher T. Ritchlin, et al.
Annals of the Rheumatic Diseases (2016) Vol. 76, Iss. 1, pp. 79-87
Open Access | Times Cited: 502
The pathogenesis of psoriatic arthritis
Douglas J. Veale, Ursula Fearon
The Lancet (2018) Vol. 391, Iss. 10136, pp. 2273-2284
Closed Access | Times Cited: 446
Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential
Wendy Dankers, Edgar M. Colin, Jan Piet van Hamburg, et al.
Frontiers in Immunology (2017) Vol. 7
Open Access | Times Cited: 401
The IL-23–IL-17 axis in inflammatory arthritis
Erik Lubberts
Nature Reviews Rheumatology (2015) Vol. 11, Iss. 7, pp. 415-429
Closed Access | Times Cited: 395
IL-17 in Chronic Inflammation: From Discovery to Targeting
Audrey Beringer, Mélissa Noack, Pierre Miossec
Trends in Molecular Medicine (2016) Vol. 22, Iss. 3, pp. 230-241
Closed Access | Times Cited: 377
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash, Bruce Kirkham, Masato Okada, et al.
The Lancet (2017) Vol. 389, Iss. 10086, pp. 2317-2327
Closed Access | Times Cited: 357
Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition
Jose U. Scher, Alexis Ogdie, Joseph F. Merola, et al.
Nature Reviews Rheumatology (2019) Vol. 15, Iss. 3, pp. 153-166
Closed Access | Times Cited: 293
Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture
Philip E. Stuart, Rajan P. Nair, Lam C. Tsoi, et al.
The American Journal of Human Genetics (2015) Vol. 97, Iss. 6, pp. 816-836
Open Access | Times Cited: 286
Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies
José María García Ruiz de Morales, L. Puig, E. Daudén, et al.
Autoimmunity Reviews (2019) Vol. 19, Iss. 1, pp. 102429-102429
Open Access | Times Cited: 278
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
Philip J. Mease, Désirée van der Heijde, Robert Landewé, et al.
Annals of the Rheumatic Diseases (2018), pp. annrheumdis-212687
Open Access | Times Cited: 252
'MHC-I-opathy'—unified concept for spondyloarthritis and Behçet disease
Dennis McGonagle, Sibel Zehra Aydın, Ahmet Gül, et al.
Nature Reviews Rheumatology (2015) Vol. 11, Iss. 12, pp. 731-740
Closed Access | Times Cited: 239
The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
Dennis McGonagle, Iain B. McInnes, Bruce Kirkham, et al.
Annals of the Rheumatic Diseases (2019) Vol. 78, Iss. 9, pp. 1167-1178
Open Access | Times Cited: 207
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
Philip J. Mease, Alice B. Gottlieb, Désirée van der Heijde, et al.
Annals of the Rheumatic Diseases (2017) Vol. 76, Iss. 9, pp. 1550-1558
Open Access | Times Cited: 196
Psoriatic arthritis
Oliver FitzGerald, Alexis Ogdie, Vinod Chandran, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 194
Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis
Maya H Buch, Stephen Eyre, Dennis McGonagle
Nature Reviews Rheumatology (2020) Vol. 17, Iss. 1, pp. 17-33
Closed Access | Times Cited: 191
Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype
Oliver FitzGerald, Muhammad Haroon, Jon T. Giles, et al.
Arthritis Research & Therapy (2015) Vol. 17, Iss. 1
Open Access | Times Cited: 182
Psoriatic Arthritis: Pathogenesis and Targeted Therapies
Ana Belén Azuaga, Julio Ramírez, Juan D. Cañete
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4901-4901
Open Access | Times Cited: 76
Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis
John Bowes, Ashley Budu‐Aggrey, Ulrike Hüffmeier, et al.
Nature Communications (2015) Vol. 6, Iss. 1
Open Access | Times Cited: 173
T cell responses in psoriasis and psoriatic arthritis
Marco Diani, G. F. Altomare, Eva Reali
Autoimmunity Reviews (2014) Vol. 14, Iss. 4, pp. 286-292
Closed Access | Times Cited: 144
Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis
Eric Gracey, Lars Vereecke, Dermot McGovern, et al.
Nature Reviews Rheumatology (2020) Vol. 16, Iss. 8, pp. 415-433
Closed Access | Times Cited: 136
The role of IL 23 in the treatment of psoriasis
L. Puig
Expert Review of Clinical Immunology (2017) Vol. 13, Iss. 6, pp. 525-534
Closed Access | Times Cited: 132
Page 1 - Next Page

Scroll to top